Table 1.

Effects of CsA on the renal abundance of mRNAa

mRNALocation7d CsA28d CsA
NKCC2Co55 ± 5b44 ± 8b
NKCC2OM108 ± 889 ± 8c
NCCCo40 ± 1b15 ± 2b,c
Na+,K+-ATPAse α1Co80 ± 243 ± 2b,c
Na+,K+-ATPAse α1OM79 ± 1066 ± 4b
TonEBPCo94 ± 693 ± 3
TonEBPOM69 ± 356 ± 4b
TonEBPIM66 ± 2b69 ± 7b
AQP2Co45 ± 5b36 ± 6b
AQP2OM122 ± 4040 ± 3b,c
AQP2IM96 ± 1852 ± 9b,c
UT-A2OM71 ± 1843 ± 5b,c
UT-A1IM95 ± 2571 ± 17
ARIM66 ± 1313 ± 5b,c
  • a Rats were treated with vehicle or cyclosporin A (CsA) for 7 (7d CsA) or 28 days (28d CsA) as described in Figure 1. RNA was extracted from cortices (Co), outer medullas (OM), and inner medullas (IM) from the kidneys, and ribonuclease protection assay (RPA) was performed to quantify mRNA. Abundance of mRNA was corrected for loading as described in the text. Percentage of abundance relative to corresponding vehicle-treated sample is shown for 7d CsA and 28d CsA in means ± SEM. n = 3 for 7d CsA; n = 6 for 28d CsA. AQP2, aquaporin 2; AR, aldose reductase; NCC, sodium/chloride transporter; NKCC2, sodium/potassium/chloride transporter type 2; TonEBP, tonicity-responsive enhancer binding protein.

  • b P < 0.05 versus vehicle.

  • c P < 0.05 versus 7d CsA.